摘要
周期蛋白依赖性激酶(CDK)4/6是细胞周期的关键调节因子,能够触发细胞周期从生长期(G1期)向DNA复制期(S1期)转变。在雌激素受体阳性(ER+)乳腺癌中,CDK4/6的过度活跃非常频繁。palbocicib是一种口服的CDK4/6抑制剂,能够选择性抑制CDK4/6,恢复细胞周期控制,阻断肿瘤细胞增殖。从Ⅱ期临床实验结果来看,palbociclib的临床疗效具有非常明显的优势。
Cycle dependent protein kinase （CDK） 4/6 is the key regulatory factor to cell cycle, and can trigger cell cycle phase to change from growth period （G1 phase） to the DNA replication period （S1 phase）. In the estrogen receptor （ER＋） breast cancer, the hyperactivity of CDK4/6 is very frequent. Palbocicib is an oral CDK4/6 inhibitor, which can selectively inhibit CDK4/6, and restore the control of cell cycle, therefore to block the proliferation of tumor cells. From the results ofⅡperiod clinical trials, the clinical efficacy of palbociclib has obvious advantages.
出处
《现代药物与临床》
CAS
2014年第10期1178-1182,共5页
Drugs & Clinic
